1. Home
  2. FUNC vs CABA Comparison

FUNC vs CABA Comparison

Compare FUNC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First United Corporation

FUNC

First United Corporation

N/A

Current Price

$38.62

Market Cap

247.8M

Sector

Finance

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.50

Market Cap

200.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUNC
CABA
Founded
1900
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.8M
200.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FUNC
CABA
Price
$38.62
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$13.50
AVG Volume (30 Days)
16.7K
3.0M
Earning Date
10-20-2025
11-10-2025
Dividend Yield
2.72%
N/A
EPS Growth
56.67
N/A
EPS
3.84
N/A
Revenue
$83,662,000.00
N/A
Revenue This Year
$16.22
N/A
Revenue Next Year
$7.42
N/A
P/E Ratio
$9.94
N/A
Revenue Growth
17.79
N/A
52 Week Low
$24.66
$0.99
52 Week High
$42.50
$5.46

Technical Indicators

Market Signals
Indicator
FUNC
CABA
Relative Strength Index (RSI) 66.28 52.01
Support Level $37.74 $2.01
Resistance Level $38.69 $2.69
Average True Range (ATR) 0.73 0.21
MACD 0.26 0.02
Stochastic Oscillator 95.72 71.32

Price Performance

Historical Comparison
FUNC
CABA

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: